Sartorius Stedim: H1 EPS down 40%
(CercleFinance.com) - Sartorius Stedim Biotech has reported a 40.
4% drop in H1 2023 EPS at E2.62, with recurrent EBITDA of E415.7m, i.e. a margin of 29.7%, vs. 35.2% a year ago.
The supplier of products and services to the pharmaceutical industry announced sales that are down 18.7% at E1.4bn, i.e. down 19.6% in organic terms at constant exchange rates, with an 18.5% decrease including acquisitions.
Acknowledging that significant uncertainties surrounding the global political and economic situation remain, the group has nevertheless confirmed its FY sales and profitability forecasts.
Copyright (c) 2023 CercleFinance.com. All rights reserved.